Catalyst Pharma Settles Patent Dispute with Lupin

Catalyst Pharma ( (CPRX) ) has shared an announcement.

On August 25, 2025, Catalyst Pharmaceuticals and its licensor SERB S.A. announced a settlement agreement with Lupin Ltd. and Lupin Pharmaceuticals, resolving patent litigation over Lupin’s attempt to market a generic version of FIRDAPSE® before the expiration of its patents. Under the agreement, Lupin will not market its generic version in the U.S. before February 25, 2035, pending FDA approval, and all ongoing litigation between the parties will be terminated. Catalyst has previously settled similar litigation with other companies, but ongoing litigation with Hetero remains unresolved.

The most recent analyst rating on (CPRX) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s strong financial performance and strategic initiatives are key strengths, supported by recent corporate developments. However, technical indicators suggest caution, and uncertainties in patent litigation and product competition pose risks.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients with rare and difficult-to-treat diseases. The company prioritizes accessibility and patient care through comprehensive support services. Catalyst is headquartered in Coral Gables, Florida, and has been recognized as one of America’s Most Successful Mid-Cap Companies and one of North America’s Fastest-Growing Companies.

Average Trading Volume: 1,369,266

Technical Sentiment Signal: Buy

Current Market Cap: $2.58B

Find detailed analytics on CPRX stock on TipRanks’ Stock Analysis page.